221 filings
Page 5 of 12
424B5
3ayvnbedj11s7ohbaw0
8 Sep 20
Prospectus supplement for primary offering
4:42pm
8-K
3d17hghj5hv
8 Sep 20
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
9:16am
S-8
2vchwd vp9y4jqgasb
6 Aug 20
Registration of securities for employees
4:32pm
S-3ASR
4bhocgt
6 Aug 20
Automatic shelf registration
4:31pm
8-K
2agqboo
6 Aug 20
Entry into a Material Definitive Agreement
7:00am
8-K
e0aclrx
22 Jun 20
Entry into a Material Definitive Agreement
7:44am
8-K
ldkq1z02 jiciel7wek
10 Jun 20
Departure of Directors or Certain Officers
12:00pm
CT ORDER
52yxauwkx35bi
14 May 20
Confidential treatment order
2:12pm
CT ORDER
y1vne
13 May 20
Confidential treatment order
4:19pm
8-K
f9kpgvfid30
7 May 20
Results of Operations and Financial Condition
7:03am
8-K
051az bw1w4otqa7fd
30 Mar 20
Departure of Directors or Certain Officers
4:30pm
8-K
cc5xzh7yyo33sn1sx if
27 Feb 20
Provides Corporate Update
7:31am
S-3ASR
sqr914i9o6xzbylc
28 Jan 20
Automatic shelf registration
12:00am
8-K
ve33kqrdgtfnwr
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
745dwf 6pg53hrm
13 Dec 19
Regulation FD Disclosure
4:16pm
8-K
gen7kx 1kninso
13 Dec 19
Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral
8:30am